| (a) A screening test for CCHD using pulse oximetry
must be performed at a birthing facility that provides care to newborn
patients except as described in §37.77 of this title (relating
to Exemption from Screen). If another U.S. Federal Drug Administration
approved instrument is available, it will be posted as identified
in subsection (b) of this section.
(b) Testing procedures must be consistent with the
most current published screening algorithm and any other protocol
currently posted, linked, or referenced on the department's Newborn
Screening website at http://www.dshs.state.tx.us/newborn/.
(c) Pulse oximeters used to conduct CCHD newborn screening
must meet the standards and accuracy as determined by the Food and
Drug Administration for hospital use in newborns.
(d) Newborns in the NICU must receive CCHD screening
prior to discharge except as described in §37.77 of this title
(relating to Exemption from Screen).
|
